Clinical Data Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma BioPharma DiveInitial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.Clinical DataOncologyRead full story pharminent April 13, 2026 (Last updated: April 14, 2026) BioPharma Dive Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy. Clinical DataOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial ResultsNext: Spyre drug for inflammatory bowel disease shows promise in early study Related Stories Clinical Data Boehringer advances duo for aggressive cancers into phase 3 pharminent June 22, 2026 Clinical Data Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls short pharminent June 17, 2026 Clinical Data EHA26: BMS touts positive multiple myeloma data for two pipeline candidates pharminent June 17, 2026
